Changes in GOLD: Today and tomorrow

The Lancet Respiratory Medicine

Volumn 3, Issue 6, 2015, Pages 424-426

  Vogelmeier, Claus F ^a   Vestbo, Jørgen ^b,c   Hurd, Suzanne S ^d   Decramer, Marc ^e  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d GOLD   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DISEASE MARKER; DYSPNEA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; MORTALITY; NOTE; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; TREATMENT INDICATION; WELLBEING; INTERNATIONAL COOPERATION; LUNG; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

HUMANS; INTERNATIONALITY; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 84930839347     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00191-5     Document Type: Note

References (13)

1. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
2. Jones PW, Adamek L, Nadeau G, Banik N Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J 2013, 42:647-654.
3. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007, 62:411-415. TORCH Clinical Endpoint Committee.
4. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011, 140:331-342.
5. McDonald VM, Higgins I, Wood LG, Gibson PG Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?. Thorax 2013, 68:691-694.
6. Goldberger JJ, Buxton AE Personalized medicine vs guideline-based medicine. JAMA 2013, 309:2559-2560.
7. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192. for the ECLIPSE Investigators.
8. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012, 7:e37483. for the ECLIPSE Investigators.
9. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013, 309:2353-2361.
10. Ramírez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med 2014, 190:996-1002.
11. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 2014, 43:993-1002.
12. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011, 261:274-282. for the COPDGene Investigators.
13. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014, 371:1285-1294. for the WISDOM Investigators.